Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03526250 · OUTCOME

Progression Free Survival (PFS)

Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial) · Source last updated 2026-04-03

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
percentage of participants
Interval / dispersion
95% Confidence Interval
Time frame
At 6 months

What was measured

PFS is defined as time from initiation of protocol treatment to disease progression, recurrence, death from any cause, or date of last contact.

Analysis population: Three patients did not receive any protocol therapy and are excluded from this analysis.

Groups in this outcome

Treatment (Palbociclib)

Patients receive palbociclib PO QD on days 1-21. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Treatment (Palbociclib)20

Reported measurements

Source class 1
Values in percentage of participants · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Treatment (Palbociclib)10Not reported1.727.2Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        1.7
        upper Limit
        27.2
        value
        10
denoms
  1. counts
    1. group Id
      OG000
      value
      20
    units
    Participants
description
PFS is defined as time from initiation of protocol treatment to disease progression, recurrence, death from any cause, or date of last contact.
dispersion Type
95% Confidence Interval
groups
  1. description
    Patients receive palbociclib PO QD on days 1-21. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
    id
    OG000
    title
    Treatment (Palbociclib)
param Type
NUMBER
population Description
Three patients did not receive any protocol therapy and are excluded from this analysis.
reporting Status
POSTED
time Frame
At 6 months
title
Progression Free Survival (PFS)
type
SECONDARY
unit Of Measure
percentage of participants

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice